JP2021525783A - Ｅｒｋ阻害剤及びその使用 - Google Patents
Ｅｒｋ阻害剤及びその使用 Download PDFInfo
- Publication number
- JP2021525783A JP2021525783A JP2020568258A JP2020568258A JP2021525783A JP 2021525783 A JP2021525783 A JP 2021525783A JP 2020568258 A JP2020568258 A JP 2020568258A JP 2020568258 A JP2020568258 A JP 2020568258A JP 2021525783 A JP2021525783 A JP 2021525783A
- Authority
- JP
- Japan
- Prior art keywords
- hydroxymethyl
- benzyl
- pyrazine
- fluoro
- chloro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 C*1(*)C(C(C**)=O)NC(*)C1 Chemical compound C*1(*)C(C(C**)=O)NC(*)C1 0.000 description 6
- RYHBNJHYFVUHQT-UHFFFAOYSA-N C1OCCOC1 Chemical compound C1OCCOC1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- IHCFYNCIOKQHQQ-UHFFFAOYSA-N CC(C)Nc(nc1)cc(-c2c[n](C)c(C(NCC[O-])O)c2)c1Cl Chemical compound CC(C)Nc(nc1)cc(-c2c[n](C)c(C(NCC[O-])O)c2)c1Cl IHCFYNCIOKQHQQ-UHFFFAOYSA-N 0.000 description 1
- SIPSZGXLQFKHOC-UHFFFAOYSA-N CCC(C)(COC(C)(C)O)CBr Chemical compound CCC(C)(COC(C)(C)O)CBr SIPSZGXLQFKHOC-UHFFFAOYSA-N 0.000 description 1
- SEMBZZBLTWAJLC-UHFFFAOYSA-N CCN(C)C1=CC(NC(C)C)=NCC1CCl Chemical compound CCN(C)C1=CC(NC(C)C)=NCC1CCl SEMBZZBLTWAJLC-UHFFFAOYSA-N 0.000 description 1
- FTFHSGKASINZBY-UHFFFAOYSA-N NCc1c(CO)cccc1 Chemical compound NCc1c(CO)cccc1 FTFHSGKASINZBY-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
- C07D493/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2018/090385 | 2018-06-08 | ||
| CN2018090385 | 2018-06-08 | ||
| CN2018120975 | 2018-12-13 | ||
| CNPCT/CN2018/120975 | 2018-12-13 | ||
| PCT/CN2019/090221 WO2019233457A1 (zh) | 2018-06-08 | 2019-06-06 | Erk抑制剂及其应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021525783A true JP2021525783A (ja) | 2021-09-27 |
| JP2021525783A5 JP2021525783A5 (enExample) | 2022-05-16 |
Family
ID=68770778
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020568258A Pending JP2021525783A (ja) | 2018-06-08 | 2019-06-06 | Ｅｒｋ阻害剤及びその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US11466013B2 (enExample) |
| EP (1) | EP3805217A4 (enExample) |
| JP (1) | JP2021525783A (enExample) |
| KR (1) | KR20210018915A (enExample) |
| CN (1) | CN112204024B (enExample) |
| AU (1) | AU2019280356B2 (enExample) |
| CA (1) | CA3103055A1 (enExample) |
| IL (1) | IL279276A (enExample) |
| SG (1) | SG11202012241RA (enExample) |
| TW (1) | TW202016102A (enExample) |
| WO (1) | WO2019233457A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023505288A (ja) * | 2019-12-06 | 2023-02-08 | メッドシャイン ディスカバリー インコーポレイテッド | Ｅｒｋ阻害剤としてのチアゾロラクタム系化合物およびその使用 |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022253186A1 (zh) * | 2021-06-02 | 2022-12-08 | 南京明德新药研发有限公司 | 一种二甲基取代的噻唑并吡咯酮类化合物的晶型及其制备方法 |
| WO2022268065A1 (en) * | 2021-06-22 | 2022-12-29 | Fochon Biosciences, Ltd. | Compounds as erk inhibitors |
| EP4366733A4 (en) * | 2021-08-11 | 2025-06-25 | Landos Biopharma, Inc. | TETRAHYDROPYRAZOLOPYRIDINE ANALOGUES OF NLRX1 LIGANDS AND THEIR USES |
| WO2024218632A1 (en) * | 2023-04-17 | 2024-10-24 | Array Biopharma Inc. | Erk protein kinase inhibitors |
| KR20260019479A (ko) | 2023-05-04 | 2026-02-10 | 레볼루션 메디슨즈, 인크. | Ras 관련 질환 또는 장애를 위한 병용 요법 |
| CN121889155A (zh) | 2023-08-07 | 2026-04-17 | 锐新医药公司 | 用于治疗ras蛋白相关疾病或病症的rmc-6291 |
| CN117209485A (zh) * | 2023-08-31 | 2023-12-12 | 四川大学华西医院 | 一种具有抗肿瘤活性的嘧啶骨架类化合物及其制备方法和应用 |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026090116A2 (en) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Ras inhibitors |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
| WO2026106912A1 (en) | 2024-11-12 | 2026-05-21 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026112260A1 (en) | 2024-11-21 | 2026-05-28 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026122764A2 (en) | 2024-12-06 | 2026-06-11 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026128688A2 (en) | 2024-12-13 | 2026-06-18 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026161839A1 (en) | 2025-01-27 | 2026-07-30 | Revolution Medicines, Inc. | Ras inhibitors |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009543836A (ja) * | 2006-07-14 | 2009-12-10 | グラクソ グループ リミテッド | インドール化合物 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4783532B2 (ja) * | 2000-02-05 | 2011-09-28 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ｅｒｋのインヒビターとして有用なピラゾール組成物 |
| CN101796036A (zh) * | 2007-08-02 | 2010-08-04 | 欧加农股份有限公司 | 作为trpv1调节剂的5-苯基异噁唑-3-甲酰胺衍生物 |
| WO2016026078A1 (en) * | 2014-08-19 | 2016-02-25 | Changzhou Jiekai Pharmatech Co., Ltd. | Heterocyclic compounds as erk inhibitors |
| CN107922387B (zh) * | 2015-06-15 | 2024-11-22 | 阿沙纳生物科学公司 | Erk1与erk2的杂环抑制剂及其在癌症治疗中的应用 |
| WO2017080980A1 (en) * | 2015-11-09 | 2017-05-18 | Astrazeneca Ab | Dihydropyrrolopyrazinone derivatives useful in the treatment of cancer |
-
2019
- 2019-06-06 AU AU2019280356A patent/AU2019280356B2/en not_active Expired - Fee Related
- 2019-06-06 KR KR1020217000434A patent/KR20210018915A/ko not_active Ceased
- 2019-06-06 TW TW108119658A patent/TW202016102A/zh unknown
- 2019-06-06 CN CN201980031574.6A patent/CN112204024B/zh not_active Expired - Fee Related
- 2019-06-06 JP JP2020568258A patent/JP2021525783A/ja active Pending
- 2019-06-06 CA CA3103055A patent/CA3103055A1/en active Pending
- 2019-06-06 EP EP19815477.5A patent/EP3805217A4/en not_active Withdrawn
- 2019-06-06 US US16/973,335 patent/US11466013B2/en active Active
- 2019-06-06 SG SG11202012241RA patent/SG11202012241RA/en unknown
- 2019-06-06 WO PCT/CN2019/090221 patent/WO2019233457A1/zh not_active Ceased
-
2020
- 2020-12-08 IL IL279276A patent/IL279276A/en unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009543836A (ja) * | 2006-07-14 | 2009-12-10 | グラクソ グループ リミテッド | インドール化合物 |
Non-Patent Citations (10)
| Title |
|---|
| BUENO, JOSE MARIA; 他: "Design, synthesis and antimalarial evaluation of novel thiazole derivatives", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 26(16), JPN6023021210, 2016, pages 3938 - 3944, ISSN: 0005227389 * |
| ＤＡＴＡＢＡＳＥ REGISTRY ＯＮ STN, JPN7023002006, ISSN: 0005227397 * |
| ＤＡＴＡＢＡＳＥ REGISTRY ＯＮ STN, JPN7023002007, ISSN: 0005227396 * |
| ＤＡＴＡＢＡＳＥ REGISTRY ＯＮ STN, JPN7023002008, ISSN: 0005227395 * |
| ＤＡＴＡＢＡＳＥ REGISTRY ＯＮ STN, JPN7023002009, ISSN: 0005227394 * |
| ＤＡＴＡＢＡＳＥ REGISTRY ＯＮ STN, JPN7023002010, ISSN: 0005227393 * |
| ＤＡＴＡＢＡＳＥ REGISTRY ＯＮ STN, JPN7023002011, ISSN: 0005227392 * |
| ＤＡＴＡＢＡＳＥ REGISTRY ＯＮ STN, JPN7023002012, ISSN: 0005227391 * |
| ＤＡＴＡＢＡＳＥ REGISTRY ＯＮ STN, JPN7023002013, ISSN: 0005227390 * |
| GUERRERO, MIGUEL; 他: "Discovery, design and synthesis of the first reported potent and selective sphingosine-1-phosphate 4", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 21(12), JPN6023021211, 2011, pages 3632 - 3636, ISSN: 0005227388 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023505288A (ja) * | 2019-12-06 | 2023-02-08 | メッドシャイン ディスカバリー インコーポレイテッド | Ｅｒｋ阻害剤としてのチアゾロラクタム系化合物およびその使用 |
| JP7409719B2 (ja) | 2019-12-06 | 2024-01-09 | 徳昇済医薬（無錫）有限公司 | Ｅｒｋ阻害剤としてのチアゾロラクタム系化合物およびその使用 |
Also Published As
| Publication number | Publication date |
|---|---|
| US20210261552A1 (en) | 2021-08-26 |
| IL279276A (en) | 2021-01-31 |
| CN112204024A (zh) | 2021-01-08 |
| TW202016102A (zh) | 2020-05-01 |
| KR20210018915A (ko) | 2021-02-18 |
| EP3805217A4 (en) | 2022-03-23 |
| AU2019280356B2 (en) | 2022-09-29 |
| US11466013B2 (en) | 2022-10-11 |
| SG11202012241RA (en) | 2021-01-28 |
| CA3103055A1 (en) | 2019-12-12 |
| EP3805217A1 (en) | 2021-04-14 |
| AU2019280356A1 (en) | 2021-01-14 |
| WO2019233457A1 (zh) | 2019-12-12 |
| CN112204024B (zh) | 2024-03-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112204024B (zh) | Erk抑制剂及其应用 | |
| JP7202315B2 (ja) | ベンズイミダゾロン由来のｂｃｌ６阻害剤 | |
| EP2686318B1 (en) | Pyrrolopyridineamino derivatives as mps1 inhibitors | |
| JP7605486B2 (ja) | キナーゼ阻害剤としての置換された縮合複素芳香族二環式化合物およびその使用 | |
| JP6564406B2 (ja) | カゼインキナーゼ１デルタ／イプシロン阻害剤としてのイミダゾ−ピリダジン誘導体 | |
| TW202016113A (zh) | Erk抑制劑及其應用 | |
| JP2022530383A (ja) | キナゾリン化合物及びその医薬上の使用 | |
| CA3198809A1 (en) | Heterocyclic spiro compounds and methods of use | |
| JP6297570B2 (ja) | 薬理活性化合物 | |
| WO2012080284A2 (en) | Substituted 6,6-fused nitrogenous heterocyclic compounds and uses thereof | |
| CN104837829A (zh) | 抑制剂化合物 | |
| KR20070104936A (ko) | 화합물 | |
| CA3107365A1 (en) | Pyrazine compounds and uses thereof | |
| CN122010947A (zh) | 腺苷A2a受体的拮抗剂 | |
| JP6283688B2 (ja) | カゼインキナーゼ１ｄ／ｅ阻害剤としての新規なピラゾール置換のイミダゾピラジン | |
| CN118043327A (zh) | Fgfr抑制剂及其使用方法 | |
| TW202122382A (zh) | 乙內醯脲衍生物 | |
| AU2021290208A1 (en) | Tricyclic compounds | |
| CN115536660A (zh) | 苄氨基取代的杂多环化合物及其组合物、制剂和用途 | |
| CN116249696B (zh) | 嘧啶酮类化合物及其用途 | |
| HK40042218A (en) | Erk inhibitor and use thereof | |
| WO2023134582A1 (zh) | 一种嘧啶-2,4-二胺衍生物及其制备方法和用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220506 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220506 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20230427 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230530 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20231226 |